- About us
- A new Institute dedicated to combating Leukemia
- Medical-scientific program
- History of Hematology on the Saint-Louis Campus
- Institute Governance
- Press Room
- Contact us
- Our news
- Profile of Valéria Bisio, Research Officer
- Establishment of a Hemato-Oncogenetics Unit
- Profile of Alice Gros, a peer-support patient
- Laureates of the first call for projects of the Leukemia Institute
- Profile of Julien Calvo, researcher
- Support us
- Join us
- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Discover the Leukemia Institute
- Researchers
- Research
- Clinical trials
- Discover the Leukemia Institute
- Healthcare professionals
- Refer a patient
- Our clinical research
- Discover the Leukemia Institute
- Industry partners
- Discover the Leukemia Institute
- Translational research
- Donors
- Support us
- Discover the Leukemia Institute
- Care
- Patient care
- Being Treated at the Leukemia Institute
- Anti-cancer Treatments
- Supportive Care
- Open Multidisciplinary Meetings
- Our clinical services
- Department of clinical hematology
- Department of adult hematology
- Hematology Transplant Unit
- Department of Pharmacology and Clinical Investigations
- Department of clinical hematology and cell therapy
- Adolescent and Young Adult Unit
- Outpatient Hemato-oncogenetics Unit
- Department of senior hematology
- Department of pediatric hematology and immunology
- Our medical laboratories
- Hematology Medical Laboratory, Michaela Fontenay
- Hematology Medical Laboratory, Jean Soulier
- Molecular Genetics Unit, Hélène Cavé
- Hematology Medical Laboratory, Vahid Asnafi
- Patient Information
- Acute Myeloid Leukemias
- Acute Lymphoblastic Leukemias
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Anti-cancer Treatments
- Supportive Care
- Psychological Support
- Research
- Our research teams
- Molecular pathology
- Functional precision medicine for leukemia
- Normal and pathological hematopoiesis
- Niche, Cancer, and Radiation in Hematopoiesis
- Population Evolution and Interaction Particle Systems
- Translational Immunology in Immunotherapy and Hematology (TIGITH)
- Identification and targeting of extrinsic regulators of myeloid malignancies
- Lymphoid niches, Chemokines and Immuno-hematological syndromes
- Molecular Mechanisms of Acute Myeloid Leukemia Development
- Chronic Myeloid Malignancies, Microenvironment & Translational Research
- Leukemia & Niche Dynamics
- Genetic and Epigenetic control of Normal and Malignant Hematopoiesis
- Stem cell dysfunction and secondary AML
- Biostatistics and clinical epidemiology
- Our technological platforms
- Our clinical research
Accueil » » Outpatient Hemato-oncogenetics UnitOutpatient Hemato-oncogenetics Unit
...Marie Sébert
Head of department
Access and contact
Saint-Louis Hospital
1 avenue Claude Vellefaux
75010 PARIS
Book an Appointment : 01 42 49 91 40
Secretariat : 01 71 20 70 18
Secretariat : 01 71 20 70 19
Department activities
We manage genetic predispositions to malignant hematologic disorders.
Germline predispositions to Hematopoietic Myeloid Malignancies currently account for approximately 10% of patients and represent a significant risk factor for these conditions.
Our clinical-biological unit manages families carrying a genetic predisposition to Hematopoietic Myeloid Malignancies or with a family history suggestive of such a predisposition. This includes both affected patients and healthy relatives who are carriers.
Families are seen either in outpatient consultations or in a dedicated day hospital setting, which allows for comprehensive care involving multiple professionals (physicians, genetic counsellors, psychologists) and the performance of necessary procedures and sampling for genetic diagnosis or follow-up, in close integration with the laboratory.
Multidisciplinary Team Meetings
The participants include clinical or laboratory hematologists, pediatricians, geneticists, genetic counsellors, psychologists, advanced practice nurses, and sometimes oncologists.
The cases presented may include:
- Discussions on the indications for germline genetic screening to be performed in a patient or family (through dedicated panels or as part of a pre-indication under the France Genomic Medicine Plan);
- Discussions to determine the pathogenicity of identified variants;
- Discussions to establish follow-up and prevention recommendations for patients and relatives who are carriers of a genetic predisposition.
Team members
Marie SébertUniversity Professor and Hospital PractitionerLise LarcherHospital PractitionerAlexia FournierGenetic counsellorAlexia FournierPsychologistAnne Le BoudecPsychologistVanessa Waldung, Laetita Adam and Selin TurkSecretariat (Shared secretariat with the senior hematology department)Featured research projects
MYELOGEN
Impact of disclosing a genetic predisposition in the care pathway of patients with acute myeloid leukemia and their families. A humanities and social sciences project
Anne Couprie (Master’s 2), co-supervised by Catherine Bourgain (INSERM, CERMES3) and Marie Sébert
PROMYLE
Single-cell study of clonal evolution in patients with constitutional DDX41 mutations
Master’s 2 and doctoral thesis by Lucie Freiman, co-supervised by Matthieu Duchmann and Marie Sébert
Project to establish a national prospective database of carriers of DDX41 variants
Project to establish a national prospective database of carriers of DDX41 variants with an associated biobank
Marie Sébert
Follow our actions by subscribing to the institute's newsletter
- Discover the Leukemia Institute
- Translational research
- Our clinical research
- Clinical trials
- Become an expert patient
- To be cared for and supported
- A new Institute dedicated to combating Leukemia